Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 3/20 | 0.46 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.46 |
| ▸ | PTGIR | P43119 | 1/20 | 0.43 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2205141 | 1.00 | PPARA (0.46) | PPARAPPARGHIF1APTGIRTAAR1 | |
| SCHEMBL19291759 | 1.00 | PPARA (0.46) | PPARAPPARGHIF1APTGIRTAAR1 | |
| SCHEMBL13881547 | 0.94 | PPARA (0.48) | PPARAPPARGHIF1APTGIRTAAR1 | |
| SCHEMBL13881578 | 0.91 | PPARA (0.52) | PPARAPPARGHIF1APTGIRS1PR1 | |
| SCHEMBL4568902 | 0.91 | PPARA (0.52) | PPARAPPARGHIF1APTGIRTSHR | |
| SCHEMBL17031425 | 0.87 | PPARA (0.44) | PPARAPPARGHIF1APTGIRTAAR1 | |
| SCHEMBL23116532 | 0.87 | MEN1 (0.48) | CYP2D6HTR2A | |
| SCHEMBL2208855 | 0.86 | TAAR1 (0.45) | PPARAPPARGPTGIRTAAR1CYP2D6 | |
| SCHEMBL19291801 | 0.85 | TAAR1 (0.44) | PPARAPPARGPTGIRTAAR1CYP2D6 | |
| SCHEMBL20332390 | 0.84 | TAAR1 (0.43) | PPARAPPARGPTGIRTAAR1CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2024-07-09 | — | — | US | disclosed |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2022-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12029708-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | PPARA 586/4885PPARG 136/4885HIF1A 1254/4885 |
| US-11446261-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | PPARA 586/4885PPARG 136/4885HIF1A 1254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.